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Abstract
Introduction: Haemophilia B (HB) is less well studied than haemophilia A (HA); despite
similarities between the two inherited bleeding disorders, important differences remain that require further research.
Aim: B-Natural is a multi-centre, prospective, observational study of HB, designed
to increase understanding of clinical manifestations, treatment, quality-of-life (QoL),
inhibitor development, immune tolerance induction (ITI) outcome, renal function and

Funding information
Biogen/Bioverativ/Sanofi; Swedish
Orphan Biovitrum (Sobi)

create a biorepository for future investigations.
Methods: Participants include sibling pairs/groups without a current/history of inhibitors and singletons or siblings with a current/history of inhibitors followed for
six months. Demographics, medical, social history and treatment were recorded. A
physical examination including joint range of motion (ROM) was performed; QoL was
assessed. Samples were collected for F9 gene mutation, HLA typing, non-inhibitory
antibodies and renal function testing.
Results: Twenty-four centres enrolled 224 individuals from 107 families including 29 with
current/history of inhibitors. Of these, 68, 30.4%, had severe (<1% FIX level of normal);
114, 50.9%, moderate (1%-5%); and 42, 18.8%, mild (>5-<40%) disease. At enrolment,
53.1% had 50 + exposure days to exogenous FIX. Comparison of joint scores showed
significant (P < .05) differences between those with severe (with/without inhibitors), and
those with moderate/mild disease. The majority with severe disease, 80.0% with current/
history of inhibitors and 64.3% of those without, were treated with prophylaxis.
Conclusion: B-Natural provides data supporting an increased understanding of HB
and its impact throughout life. The need for optimal disease control to normalize
physical and psychosocial outcomes is underscored, and further analyses will contribute to an increased understanding of critical issues in HB.
KEYWORDS

factor IX deficiency, FIX inhibitors, haemophilia B, joint range-of-motion, quality-of-life,
treatment
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I NTRO D U C TI O N

Major bleeding sites in both HA and HB include joints and muscles, haematuria, mucocutaneous bleeding and intracranial haemor-

Haemophilia B (HB), factor IX (FIX) deficiency, is the second most

rhage. There are no consistent data to support a difference in the

common type of haemophilia, occurring in about one in 25 000 male

bleeding phenotype of patients with HA and HB.

births. This disease is less well studied than haemophilia A (HA).

The Factor IX Treatment Network was formed to investigate the

While there are several similarities between the two, including types

treatment, outcomes, and complications of HB and provide an im-

of bleeding events—primarily haemarthroses—and inhibitor devel-

proved understanding of the disease.10 To shed more light on the

opment, there are important differences as well. These include the

clinical manifestations of HB, the Network initiated the B-Natural

frequency of occurrence, variation in the distribution of severities,1-3

study, in which two groups of subjects with FIX deficiency are ex-

predominance of types of gene mutations, factors associated with

amined—those with a current or history of inhibitors to FIX, and

inhibitor development, ability to achieve tolerance with immune tol-

groups of two or more affected siblings, with or without inhibitors.

erance induction (ITI) and risk of ITI-associated sequelae.

Enrolment of siblings permits within-family examination of clinical

While the incidence of inhibitors among those with severe HA

outcomes to document the degree of concordance with minimized

is approximately 25%-30%, it is closer to 5% in severe HB 4-6 and

variation of relevant genetic factors. The primary objective was to

7

up to 10% in one recent study. While incidence is lower, inhibi-

characterize the study group in terms of medical history, patterns of

tors are associated with increased frequency of anaphylactoid re-

bleeding, care, quality of life (QoL) and complications including the

actions
of ITI.9

8,9

and, based upon small series, less successful outcome

development of inhibitory antibodies to FIX, allergy, renal and joint
disease. The current manuscript addresses the design and methods

|
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of B-Natural and provides a description of the participants and an

was completed by a caregiver for those 4-8 years, and the EQ-5D-Y

overview of their treatment, joint status and QoL.

Youth version for those 8-16 years of age.

2

2.5 | Statistical methods

|

M E TH O D S

2.1 | Design and eligibility

All statistical analyses were performed in the R language.12
Descriptive statistics including means (standard deviations) and

B-Natural is a multi-centre, prospective, observational study.

medians [25th percentile, 75th percentile] were used. Relationships

Subjects were eligible to participate if they had FIX deficiency and

between continuous variables were examined with linear regression

were part of an affected sibling pair/group; and/or had a current or

and Pearson correlation coefficients.

history of inhibitor, defined as > 0.6 Bethesda units (BU). Participants

The procedures followed were approved by the ethical com-

were followed for six months with in-person visits at enrolment and

mittees in each participating centre. B-Natural is registered at

study termination. Tests to determine eligibility (inhibitor, clotting

ClinicalTrials.gov (NCT02502409).

factor level) were performed in the local laboratories. Blood and
urine samples were collected for central laboratory typing of F9
gene mutation (if not already determined) and HLA, non-inhibitory
antibody and renal function testing, and repository storage for future haemophilia-related studies.

2.2 | Clinical and demographic characteristics

3

|

R E S U LT S

3.1 | Clinical and demographic characteristics
Twenty-four centres participated, 16 in North America, seven in
Europe and one in Asia. From the population under care at participating centres, a total of 392 potential subjects were identified.

Demographics, including date of birth, race/ethnicity, a medical and

Two hundred and twenty-four individuals ranging in age from 1

social history, and a haemophilia-related history were obtained. In

to 73 from 107 families were enrolled between January 2016 and

addition to severity of FIX deficiency (mild = >5% - <40%; moder-

February 2018:167 (74.6%), median age 12.8, in North America; 38

ate = 1-5; severe = <1% FIX level of normal), factors related to early

(17.0%), median age 18.4, in Europe; and 19 (8.5%), median age 13.7,

treatment and product use were recorded. If the participant had a

in Asia. Data collection covered the period January 2015 through

history of an inhibitor, information including characteristics of the

November 2018. The mean centre enrolment rate was 78.8%, the

inhibitor was collected. Data were collected to describe the use of

median 53.2% [25th, 75th percentiles: 40.0%, 83.6%]. Figure 1 and

ITI and overall success. A brief physical examination was performed

Table 1 show the distribution and characteristics of families and par-

including weight and height, from which body mass index (BMI) was

ticipants across severity and inhibitor status. Of the 224 individuals

calculated (kg/m2).

enrolled, 68 (30.4%) had severe FIX deficiency, 114 (50.9%) moderate and 42 (18.8%) mild. Twenty-nine had a current or history of

2.3 | Joint assessment

an inhibitor. Twenty-one families contained members with mixed
severities: severe and moderate (N = 4 families), and moderate and
mild (N = 17 families). Three families contained siblings discordant

Range-of-motion (ROM) for elbows, knees, and ankles was as-

for inhibitor status. By the time of the first visit, 53.1% of partici-

sessed by qualified staff trained in joint measurement. A four-point

pants had 50 + exposure days to FIX replacement therapy, 93.1% of

scale was used: 0 = No loss of total full range of motion (FROM);
1 = Loss of < 10% of total FROM; 2 = Loss of 10-33⅓% of total

those with inhibitors and 47.2% of those without.

FROM; 3 = Loss of > 33⅓% of total FROM. This method was chosen

All subjects with inhibitors had severe disease. Of the 29, 13 had

primarily for feasibility and the belief that each centre would be able

peak titres ≤ 5 Bethesda Units (BU), 13 had peak titres > 5 BU, and

to reliably provide the measurements. A composite score was calcu-

for three the peak titre was unknown. Twenty-two underwent one or

lated by summing the FROM scores for each joint, ranging from 0, no

more courses of ITI. Eleven of these were deemed successfully tol-

loss of FROM in any joint evaluated, to 18, loss of > 33⅓ in all joints.

erized by the investigator at the conclusion of B-Natural follow-up.

2.4 | Health-related quality of life

3.2 | Haemophilia treatment in the year prior
to enrolment

The EQ-5D instruments11 were used to measure health-related QoL
at study entry. The EQ-5D-5L Self-given health questionnaire was

Of the 224 subjects enrolled, 196 (87.5%) were able to report the

used for participants 16 + years of age, the EQ-5D-5L Proxy version

treatment burden defined by the estimated number of infusions of

52
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F I G U R E 1 Distribution of families and individual participants across severity of factor IX deficiency. The number of families in each
category is shown with the number of individuals in each group in parentheses

TA B L E 1 Characteristics of study participants by severity groupa

Age

Inhibitor

No Inhibitor

N = 29

Severe (<1%)
N = 39

Moderate (1%-5%)
N = 114

Mild (>5%)
N = 42

N

16.5 [8.08; 31.9]

15.4 [11.0; 32.3]

13.3 [8.58;20.3]

12.1 [7.65; 20.8]

224

23.3 (20.5)

22.6 (16.9)

16.9 (12.5)

17.1 (14.1)

224

Age group:

224

<6

5 (17.2%)

3 (7.69%)

14 (12.3%)

7 (16.7%)

6-17

10 (34.5%)

19 (48.7%)

63 (55.3%)

23 (54.8%)

18-49

11 (37.9%)

13 (33.3%)

34 (29.8%)

11 (26.2%)

50+

3 (10.3%)

4 (10.3%)

3 (2.63%)

1 (2.38%)

Female

0 (0.00%)

0 (0.00%)

0 (0.00%)

4 (9.52%)

Male

29 (100%)

39 (100%)

114 (100%)

38 (90.5%)

Gender:

224

Ethnicity:

224

Asian

0 (0.00%)

7 (17.9%)

13 (11.4%)

0 (0.00%)

Black

5 (17.2%)

8 (20.5%)

2 (1.75%)

0 (0.00%)

Hispanic

1 (3.45%)

0 (0.00%)

2 (1.75%)

2 (4.76%)

White

22 (75.9%)

24 (61.5%)

96 (84.2%)

40 (95.2%)

Other
BMI (kg/m2)

1 (3.45%)

0 (0.00%)

1 (0.88%)

0 (0.00%)

21.9 [17.8;25.6]

19.9 [16.6;27.9]

20.0 [16.0;23.6]

20.4 [16.5;25.4]

223

23.7 (7.85)

22.4 (7.60)

20.8 (5.97)

21.4 (6.18)

223

a

Continuous variable statistics are displayed as: median [25th percentile, 75th percentile] and mean (standard deviation) in two separate rows.
Categorical variable statistics are displayed as frequency counts (per cents).

replacement products or bypassing agents used in the prior year.

those without, were treated with prophylaxis (Table 3). Excluding

Forty-nine (25%) reported no infusions. The mean and median num-

one centre with a lower level of resourcing, the proportion among
those without inhibitors increased to 75.0% (data not shown). The

bers of infusions by inhibitor status and severity are shown in Table 2.

types of replacement product(s) used are shown in Table 4. Type of

The majority of subjects with severe FIX deficiency, 80.0%

product(s) varied by region and subjects might have been exposed

among those with a current or history of inhibitors and 64.3% of

to more than one type of product or received no infusions during

|
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TA B L E 2 Estimated number of infusions of replacement products or bypassing agents in the year prior to enrolment a

No. infusions

a

Inhibitor

No Inhibitor

N = 25

Severe (<1%)
N = 28

Moderate (1%-5%)
N = 104

Mild (>5%)
N = 39

N

180 [115;200]

51.0 [19.5;104]

3.00 [0.00;11.0]

1.00 [0.00;3.00]

196

184 (145)

57.0 (45.3)

12.3 (24.8)

4.54 (9.58)

196

Continuous variable statistics are displayed as: median [25th percentile, 75th percentile] and mean (standard deviation) in two separate rows.

TA B L E 3 Treatment in the year prior
to enrolment among subjects with nonmissing number of infusionsa

Inhibitor

No inhibitor

N

N = 25

Severe (<1%)
N = 28

Moderate (1%5%) N = 104

Mild (>5%)
N = 39

On-demand

5 (20.0%)

10 (35.7%)

95 (91.3%)

39 (100.0%)

Prophylaxis

20 (80.0%)

18 (64.3%)

9 (8.7%)

0 (0.0%)

196

Treatment:

a

Categorical variable statistics are displayed as frequency counts (per cents).

TA B L E 4 Type of treatment in year prior to enrolment a
Inhibitor

No inhibitor

N = 25

Severe (<1%)
N = 28

Moderate (1%-5%)
N = 104

Mild (>5%)
N = 39

1. Plasma/prothrombin complex concentrates/whole blood

0 (0.00%)

4 (14.3%)

7 (6.73%)

0 (0.00%)

2. Plasma derived: non-monoclonal antibody purified

2 (8.00%)

3 (10.7%)

2 (1.92%)

0 (0.00%)

3. Plasma derived: monoclonal antibody purified

5 (20.0%)

1 (3.57%)

1 (0.96%)

0 (0.00%)

4. Recombinant: standard half-life molecule

14 (56.0%)

13 (46.4%)

63 (60.6%)

19 (48.7%)

5. Recombinant: extended half-life molecule

1 (4.00%)

10 (35.7%)

8 (7.69%)

2 (5.13%)

5 (20.0%)

0 (0.00%)

0 (0.00%)

0 (0.00%)

6. Other

b

N
196

a

Subjects with non-missing estimated number of infusions in the year prior to enrolment. Categorical variable statistics are displayed as frequency
counts (per cents). Subjects may have received more than one type of product in the year prior to enrolment or received no infusions during the
period.
b

rFVIIa and FEIBA

the period. In the North American centres, recombinant standard

of FROM composite score over age shows significant (P < .05) differ-

half-life products were used by 63.2% of subjects, recombinant ex-

ences between the groups with severe deficiency (with or without

tended half-life products by 9.7%, plasma-derived monoclonal puri-

inhibitor) and those with moderate or mild disease.

fied products by 2.6%, non-monoclonal purified products by 0.6%
and bypassing agents by 2.6%. In European centres, the percentages
were 36.7%, 20.0%, 10.0%, 20.0% and 3.3%, respectively. The dif-

3.4 | Quality-of-life

ference in type of product used (plasma derived vs. recombinant)
between North America and Europe is largely explained by partici-

Figure 3 combines data from the three versions of the EQ-5D instru-

pant age. Use of recombinant products was significantly related to

ment to show the proportions of individuals reporting problems in

younger age in both geographic areas and subjects enrolled in North

each of the dimensions by severity group. Fifteen participants were

America were significantly younger than those in Europe. In the

too young (<4 years of age) to have been assessed.

Asian centre, plasma/prothrombin complex concentrates and whole
blood were used exclusively.

3.3 | Joint assessment

3.5 | Early treatment
Participants with severe haemophilia (with or without inhibitors)
were more likely to begin treatment within the first year of life,

Table 5 presents the distribution of FROM of each joint and a com-

whereas onset of treatment for those with moderate or mild disease

posite score. In Figure 2, a comparison of the linear regression slopes

most commonly occurred between one and five years of age. Across

54
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TA B L E 5 Joint assessment: loss of total free range of motion (FROM)a
Inhibitor

No Inhibitor

N = 29

Severe (<1%)
N = 39

Moderate (1%-5%)
N = 114

Mild (>5%)
N = 42

Left ankle

N
224

No loss

15 (51.7%)

26 (66.7%)

90 (78.9%)

40 (95.2%)

Loss of < 10%

3 (10.3%)

5 (12.8%)

9 (7.89%)

1 (2.38%)

Loss of 10%-33.3%

2 (6.90%)

2 (5.13%)

13 (11.4%)

0 (0.00%)

Loss of > 33.3

7 (24.1%)

6 (15.4%)

1 (0.88%)

0 (0.00%)

Not assessed

1 (3.45%)

0 (0.00%)

0 (0.00%)

0 (0.00%)

‘Missing’

1 (3.45%)

0 (0.00%)

1 (0.88%)

1 (2.38%)

No loss

13 (44.8%)

26 (66.7%)

87 (76.3%)

40 (95.2%)

Loss of < 10%

1 (3.45%)

2 (5.13%)

11 (9.65%)

1 (2.38%)

Loss of 10%-33.3%

5 (17.2%)

6 (15.4%)

13 (11.4%)

0 (0.00%)

Loss of > 33.3%

7 (24.1%)

5 (12.8%)

1 (0.88%)

0 (0.00%)

Not assessed

2 (6.90%)

0 (0.00%)

1 (0.88%)

0 (0.00%)

‘Missing’

1 (3.45%)

0 (0.00%)

1 (0.88%)

1 (2.38%)

Right ankle

224

Left knee

224

No loss

17 (58.6%)

29 (74.4%)

99 (86.8%)

39 (92.9%)

Loss of < 10%

0 (0.00%)

0 (0.00%)

7 (6.14%)

2 (4.76%)

Loss of 10%-33.3%

4 (13.8%)

6 (15.4%)

6 (5.26%)

0 (0.00%)

Loss of > 33.3%

6 (20.7%)

4 (10.3%)

1 (0.88%)

0 (0.00%)

Not assessed

1 (3.45%)

0 (0.00%)

0 (0.00%)

0 (0.00%)

‘Missing’

1 (3.45%)

0 (0.00%)

1 (0.88%)

1 (2.38%)

No loss

14 (48.3%)

26 (66.7%)

100 (87.7%)

38 (90.5%)

Loss of < 10%

3 (10.3%)

0 (0.00%)

6 (5.26%)

2 (4.76%)

Loss of 10%-33.3%

2 (6.90%)

6 (15.4%)

6 (5.26%)

0 (0.00%)

Loss of > 33.3%

7 (24.1%)

7 (17.9%)

1 (0.88%)

0 (0.00%)

Not assessed

2 (6.90%)

0 (0.00%)

0 (0.00%)

1 (2.38%)

‘Missing’

1 (3.45%)

0 (0.00%)

1 (0.88%)

1 (2.38%)

Right knee

224

Left elbow

224

No loss

13 (44.8%)

31 (79.5%)

95 (83.3%)

41 (97.6%)

Loss of < 10%

2 (6.90%)

2 (5.13%)

14 (12.3%)

0 (0.00%)

Loss of 10%-33.3%

8 (27.6%)

5 (12.8%)

4 (3.51%)

0 (0.00%)

Loss of > 33.3%

4 (13.8%)

1 (2.56%)

0 (0.00%)

0 (0.00%)

Not assessed

1 (3.45%)

0 (0.00%)

0 (0.00%)

0 (0.00%)

‘Missing’

1 (3.45%)

0 (0.00%)

1 (0.88%)

1 (2.38%)

No loss

16 (55.2%)

31 (79.5%)

96 (84.2%)

40 (95.2%)

Loss of < 10%

3 (10.3%)

2 (5.13%)

14 (12.3%)

0 (0.00%)

Loss of 10%-33.3%

1 (3.45%)

3 (7.69%)

1 (0.88%)

1 (2.38%)

Loss of > 33.3%

7 (24.1%)

3 (7.69%)

1 (0.88%)

0 (0.00%)

Not assessed

1 (3.45%)

0 (0.00%)

1 (0.88%)

0 (0.00%)

‘Missing’

1 (3.45%)

0 (0.00%)

1 (0.88%)

1 (2.38%)

3.00 [0.00;12.0]

0.00 [0.00;5.00]

0.00 [0.00;2.00]

0.00 [0.00;0.00]

216

6.35 (7.01)

3.72 (5.37)

1.46 (2.46)

0.20 (0.88)

216

Right elbow

Range of motion: composite score

224

b

a

Continuous variable statistics are displayed as: median [25th percentile, 75th percentile] and mean (standard deviation) in two separate rows.
Categorical variable statistics are displayed as frequency counts (per cents).

b

Composite scores include subjects with non-missing data for all joints.
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Inhibitor

Range of motion: composite score

No Inhibitor: Severe (<1%)

Corr: 0.65 (0.35, 0.83)
p < 0.001

15

55

Corr: 0.80 (0.64, 0.89)
p < 0.001

15

10

10

5

5

0

0

No Inhibitor: Moderate (1−5%)

No Inhibitor: Mild (>5%)

Corr: 0.31 (0.14, 0.47)
p < 0.001

15

Corr: 0.35 (0.04, 0.60)
p = 0.027

15

10

10

5

5

0

0
0

20

40

60

0

20

40

60

Age at baseline (years)

F I G U R E 2 Joint composite score by haemophilia severity and inhibitor group. A panel for each of the groups of interest shows the
linear regression line and confidence interval or range of motion composite score by age at baseline. In each panel, the Pearson correlation
coefficient, an indicator of the strength of the linear association, its 95% confidence interval and p-values are shown
all severity groups, a bleeding episode was the most common reason

clinical/phenotypic manifestations, but the findings have not been

for the first exposure (72.8%). The presence of illness or infection at

consistent and require further evaluation.16

first exposure was infrequent (5.4%).

The B-Natural study included 24 centres representing the

Prior to inhibitor development or in the first 50 exposure days,

United States, EU and one in Asia, with 224 individuals from 107

greater than 50% of all groups received on-demand treatment—

families and collected medical history, bleeding patterns, QoL and

those with severe disease were somewhat more likely to be treated

complications. B-Natural participants closely mirror the distribution

with prophylaxis, alone or in combination with on-demand, 34.5%

of severity reported in HB, but the number/percentage of moder-

(participants with inhibitors) and 48.7% (without inhibitors). Type of

ately deficient patients was enriched as the two US centres with

product varied by geographic location. In the United States, recom-

the highest enrolment have large populations of Old Order Amish

binant standard half-life products were used by 85.6% of subjects.

with HB (data not shown). These individuals have a unifying founder

In Europe, the most commonly used concentrates were plasma-de-

mutation (F9 c.1025C > T [p.Thr342Met]) that predicts moderate

rived non-monoclonal (42.1%) and recombinant standard half-life

factor IX deficiency. The enrichment of these patients provides an

products (39.5%). In Asia, plasma/prothrombin complex concen-

opportunity to improve the breadth of analysis in this category.

trates and whole blood were used exclusively.

Further, inclusion of siblings permits a comparison of phenotypic expression of disease within families, contributing more information.

4
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DISCUSSION

Interestingly, 21 families contained members with differing severities of HB. The reason for this is not clear, but may be due, in part,
to assay discordance, which has been observed in individuals with

The B-Natural study was designed to obtain an in-depth description

the same mutation. The F9 c.1025C > T mutation has been reported

of contemporary aspects of HB, including contributing factors to

128 times in the European Association for Haemophilia and Allied

inhibitor development, ITI use and outcome and associated seque-

Disorders (EAHAD) Coagulation Factor Databases, www.dbs.eahad.

lae. The study groups of most investigations related to haemophilia

org, with levels ranging from < 1% to 16%.18,20 This also occurs in

natural history and outcomes include a majority of individuals with

HA, where, for example, the F8 c.2167G > A (p.Ala723Thr) mutation,

HA, and hence, our understanding of the similarities and differences

reported 144 times in the EAHAD variant database, has levels rang-

in HB has lagged. Some studies, but not all, indicate a milder bleeding

ing from < 1 to 20%. In addition, there is known variability in assay

phenotype in HB compared to HA with a less severe HB phenotype

sensitivity across laboratories, when results are performed in sepa-

for each level of severity measured by number of reported bleeding

rate runs, based upon the source of substrate, as well as a variety of

episodes, limitations in joint ROM, hospitalizations and orthopae-

pre-analytic variables.

dic interventions.13-19 Both genetic and molecular mechanisms have

Individuals with a current or history of inhibitors, 29 of 224

been implicated as causative factors for this potential difference in

participants (12.9%), all with severe FIX deficiency, were purposely
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Proportion reporting problem
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F I G U R E 3 Proportion of subjects reporting problems in EQ-5D subscales by haemophilia severity and inhibitor status group
enriched in this study, allowing evaluation of contributors to this

and the longer half-life of FIX concentrates, both standard and ex-

complication associated with unique manifestations and outcomes

tended half-life, as compared to HA. Together, these result in a need

compared to HA. The cohort with inhibitors is relatively small; a

for fewer infusions for bleeding resolution in FIX deficiency com-

complete description and analysis of this group will be reported

pared to FVIII, as well as fewer bleeding events experienced. Prior to

separately.

inhibitor development or in the first 50 exposure days, 34.5% of par-

The participants in B-Natural spanned a wide age range (me-

ticipants with inhibitors and 48.7% of those with severe deficiency,

dian 13.6 years, range 1-73 years) and included 144 (64.3%) partici-

but without inhibitors, were treated with prophylaxis. Given pub-

pants < 18 years of age. Importantly, at the time of enrolment, 53.1%

lished guidelines for severe haemophilia, it appears that the standard

of the participants had achieved 50 + exposure days overall, most

of instituting prophylaxis, either primary (before the age of three and

commonly in the severe deficient patients > 6 years of age. Taken

before the first or second large joint bleed) or secondary (after two

together, the data collected in B-Natural provide a comprehensive

or more large joint bleeds but before the onset of chronic arthrop-

overview of HB as they span a wide age range, represent all levels of

athy)22 has not been uniformly applied to children with severe HB.

deficiency and racial/ethnic diversity from centres from across the
United States, EU and parts of Asia.

The comparison of the linear regression slopes of the joint composite score indicates significant (P < .5) differences between the

Factors impacting the number of infusions administered in the

group with severe deficiency and those with moderate or mild dis-

year prior to enrolment (Table 2) include presence or history of an

ease over time. These data support the occurrence of cumulative

inhibitor and level of severity with a median/mean higher in the se-

damage due to haemarthroses—clinical or subclinical. The smaller

vere group followed by the moderate and then mild categories, as

per cent treated with prophylaxis in severe disease may result from

expected and similar to those for HA. However, the number of infu-

the perception that it may not be required in HB due to the de-

sions is, overall, less compared to that expected in HA with severe

creased number of bleeding episodes experienced,16,18,19 that pro-

disease without an inhibitor.

21

This may be multifactorial, impacted

phylaxis, when applied, is either provided after damage has occurred

by the per cent of the population treated with prophylaxis (64.3%)

or is insufficient to adequately suppress all bleeding episodes, or
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that local health economies prohibit prophylaxis. It is documented

to suppress risk of bleeding in HA has emerged, 25 we may need to

that prophylaxis is less utilized in under- or poorly resourced health

re-evaluate HB in light of not just the frequency of bleeding but the

economies yet the vast majority of centres participating in B-Natural

sequelae of these events that accumulate over time. B-Natural pro-

represent well-supported facilities where prophylaxis is widely avail-

vides important data to support an increased understanding of the

able; prophylaxis in patients with severe deficiency and without in-

natural history of HB and its impact throughout life.

hibitors was provided in 64.3% overall, and 75.0% when one centre
with a lower level of resourcing was excluded.
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